Despite screening programs, approximately 14,000 cases of invasivecervical cancer are diagnosed annually in the United States.In approximately half these cases, locally advanced diseaseis present at the time of diagnosis. In developing countries,the disease is usually advanced by the time of diagnosis, theprevalence is much higher, and cervical cancer is the principalcause of death due to cancer in women.
Pelvic radiation has been the standard, definitive therapy foradvanced disease. With this treatment, the overall five-yearsurvival rate is approximately 65 percent, but it ranges from15 to 80 percent, depending on the extent of . . . [Full Text of this Article]
References
This article has been cited by other articles:
Panici, P. B., Bellati, F., Manci, N., Pernice, M., Plotti, F., Di Donato, V., Calcagno, M., Zullo, M. A., Muzii, L., Angioli, R.
(2007). Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer. Ann. Surg. Oncol.
14: 2643-2648
[Abstract][Full Text]
Brizel, D. M., Esclamado, R.
(2006). Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum. JCO
24: 2612-2617
[Abstract][Full Text]
Kvols, L. K.
(2005). Radiation Sensitizers: A Selective Review of Molecules Targeting DNA and non-DNA Targets. JNM
46: 187S-190S
[Abstract][Full Text]
Hedley, D., Pintilie, M., Woo, J., Nicklee, T., Morrison, A., Birle, D., Fyles, A., Milosevic, M., Hill, R.
(2004). Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis. Am. J. Pathol.
164: 557-565
[Abstract][Full Text]
Cannistra, S. A., Bast, R. C. Jr., Berek, J. S., Bookman, M. A., Crum, C. P., DePriest, P. D., Garber, J. E., Koh, W.-J., Markman, M., McGuire, W. P. III, Rose, P. G., Rowinsky, E. K., Rustin, G. J.S., Skates, S. J., Vasey, P. A., King, L.
(2003). Progress in the Management of Gynecologic Cancer: Consensus Summary Statement. JCO
21: 129s-132
[Full Text]
Koh, W.-J.
(2003). Controversies in the Radiotherapeutic Management of Cervical Cancer. JCO
21: 218s-223
[Abstract][Full Text]
Sultana, H., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Sato, S., Kamazawa, S., Ohwada, M., Suzuki, M., Terakawa, N.
(2003). Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol
14: 214-219
[Abstract][Full Text]
Davy, M. L. J., Dodd, T. J., Luke, C. G., Roder, D. M.
(2003). Cervical Cancer: Effect of Glandular Cell Type on Prognosis, Treatment, and Survival. Obstet Gynecol
101: 38-45
[Abstract][Full Text]
Fiorica, J. V.
(2002). Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan. The Oncologist
7: 36-45
[Abstract][Full Text]
Ghali, W. A., Cornuz, J., McAlister, F. A., Wasserfallen, J.-B., Devereaux, P.J., Naylor, C. D.
(2002). Accelerated publication versus usual publication in 2 leading medical journals. CMAJ
166: 1137-1143
[Abstract][Full Text]
Ferrandina, G., Lauriola, L., Distefano, M. G., Zannoni, G. F., Gessi, M., Legge, F., Maggiano, N., Mancuso, S., Capelli, A., Scambia, G., Ranelletti, F. O.
(2002). Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients. JCO
20: 973-981
[Abstract][Full Text]
(1999). Concurrent Chemotherapy and Radiotherapy for Advanced Cervical Cancer. JWatch General
1999: 3-3
[Full Text]
He, Q., Liang, C. H., Lippard, S. J.
(2000). Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA
97: 5768-5772
[Abstract][Full Text]